Elevated mRNA Level of Y-Box Binding Protein 1 Indicates Unfavorable Prognosis Correlated with Macrophage Infiltration and T Cell Exhaustion in Luminal Breast Cancer

References

• SiegelRL, MillerKD, JemalA. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.30620402
   PubMed Web of Science ®Google Scholar
• WuCY, DuSL, ZhangJ, LiangAL, LiuYJ. Exosomes and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment. Cancer Gene Ther. 2017;24(1):6–12. doi:10.1038/cgt.2016.6927982016
   PubMed Web of Science ®Google Scholar
• EngstromMJ, OpdahlS, HagenAI, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat. 2013;140(3):463–473. doi:10.1007/s10549-013-2647-223901018
   PubMed Web of Science ®Google Scholar
• GouriA, DekakenA, El BairiK, et al. Plasminogen activator system and breast cancer: potential role in therapy decision making and precision medicine. Biomark Insights. 2016;11:105–111. doi:10.4137/BMI.S3337227578963
   PubMed Web of Science ®Google Scholar
• LiX, YangJ, PengL, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279–287. doi:10.1007/s10549-016-4059-627888421
   PubMed Web of Science ®Google Scholar
• SmerageJB, BarlowWE, HortobagyiGN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J clin oncol. 2014;32(31):3483–3489. doi:10.1200/JCO.2014.56.256124888818
   PubMed Web of Science ®Google Scholar
• ChenB, LaiJ, DaiD, ChenR, LiX, LiaoN. JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer. Aging. 2019;11(23):11124–11135. doi:10.18632/aging.10251431790361
   PubMedGoogle Scholar
• KuwanoM, ShibataT, WatariK, OnoM. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019;110(5):1536–1543. doi:10.1111/cas.1400630903644
   PubMed Web of Science ®Google Scholar
• KohnoK, IzumiH, UchiumiT, AshizukaM, KuwanoM. The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays. 2003;25(7):691–698. doi:10.1002/bies.1030012815724
   PubMed Web of Science ®Google Scholar
• KretovDA, ClementMJ, LambertG, et al. YB-1, an abundant core mRNA-binding protein, has the capacity to form an RNA nucleoprotein filament: a structural analysis. Nucleic Acids Res. 2019;47(6):3127–3141. doi:10.1093/nar/gky130330605522
   PubMed Web of Science ®Google Scholar
• WoolleyAG, AlgieM, SamuelW, et al. Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS One. 2011;6(6):e20603. doi:10.1371/journal.pone.002060321695211
   PubMed Web of Science ®Google Scholar
• CohenSB, MaW, ValovaVA, et al. Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene. 2010;29(3):403–410. doi:10.1038/onc.2009.32119838214
   PubMed Web of Science ®Google Scholar
• LimJP, ShyamasundarS, GunaratneJ, ScullyOJ, MatsumotoK, BayBH. YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro. BMC Cancer. 2017;17(1):201. doi:10.1186/s12885-017-3187-728302118
   PubMed Web of Science ®Google Scholar
• MaciejczykA, SzelachowskaJ, EkiertM, et al. Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res. 2012;32(8):3177–3184.22843890
   PubMed Web of Science ®Google Scholar
• ChoKH, JeongBY, ParkCG, LeeHY. The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion. Arch Pharm Res. 2019;42(6):519–530. doi:10.1007/s12272-019-01149-631004257
   PubMed Web of Science ®Google Scholar
• EvdokimovaV, TognonC, NgT, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009;15(5):402–415. doi:10.1016/j.ccr.2009.03.01719411069
   PubMed Web of Science ®Google Scholar
• InoueI, MatsumotoK, YuY, BayBH. Surmounting chemoresistance by targeting the Y-box binding protein-1. Anatomical Record. 2012;295(2):215–222. doi:10.1002/ar.22401
   Google Scholar
• LiuSL, SuiYF, LinMZ. MiR-375 is epigenetically downregulated due to promoter methylation and modulates multi-drug resistance in breast cancer cells via targeting YBX1. Eur Rev Med Pharmacol Sci. 2016;20(15):3223–3229.27466996
   PubMed Web of Science ®Google Scholar
• WangJ, DjudjajS, GibbertL, et al. YB-1 orchestrates onset and resolution of renal inflammation via IL10 gene regulation. J Cell Mol Med. 2017;21(12):3494–3505. doi:10.1111/jcmm.1326028664613
   PubMed Web of Science ®Google Scholar
• LamanAG, LatheR, ShepelyakovskayaAO, et al. Muramyl peptides activate innate immunity conjointly via YB1 and NOD2. Innate Immun. 2016;22(8):666–673. doi:10.1177/175342591666898227694635
   PubMed Web of Science ®Google Scholar
• RhodesDR, Kalyana-SundaramS, MahavisnoV, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180. doi:10.1593/neo.0711217356713
   PubMed Web of Science ®Google Scholar
• BarretinaJ, CaponigroG, StranskyN, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–607. doi:10.1038/nature1100322460905
   PubMed Web of Science ®Google Scholar
• ChandrashekarDS, BashelB, BalasubramanyaSAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.00228732212
   PubMed Web of Science ®Google Scholar
• CeramiE, GaoJ, DogrusozU, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-009522588877
   PubMed Web of Science ®Google Scholar
• GaoJ, AksoyBA, DogrusozU, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.200408823550210
   PubMed Web of Science ®Google Scholar
• GyorffyB, LanczkyA, EklundAC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123(3):725–731. doi:10.1007/s10549-009-0674-920020197
   PubMed Web of Science ®Google Scholar
• LiT, FuJ, ZengZ, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514. doi:10.1093/nar/gkaa40732442275
   PubMed Web of Science ®Google Scholar
• LiB, SeversonE, PignonJC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. doi:10.1186/s13059-016-1028-727549193
   PubMed Web of Science ®Google Scholar
• LiT, FanJ, WangB, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-030729092952
   PubMed Web of Science ®Google Scholar
• NewmanAM, LiuCL, GreenMR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.333725822800
   PubMed Web of Science ®Google Scholar
• HallP, PlonerA, BjohleJ, et al. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med. 2006;4:16. doi:10.1186/1741-7015-4-1616813654
   PubMed Web of Science ®Google Scholar
• PawitanY, BjohleJ, AmlerL, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7(6):R953–964. doi:10.1186/bcr132516280042
   PubMed Web of Science ®Google Scholar
• VasaikarSV, StraubP, WangJ, ZhangB. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx109029136207
   PubMed Web of Science ®Google Scholar
• BoC, WuQ, ZhaoH, LiX, ZhouQ. Thymosin alpha1 suppresses migration and invasion of PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3-MMP2 signaling. Onco Targets Ther. 2018;11:7255–7270. doi:10.2147/OTT.S17794330425517
   PubMed Web of Science ®Google Scholar
• DonehowerLA, SoussiT, KorkutA, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28(5):1370–1384 e1375. doi:10.1016/j.celrep.2019.07.00131365877
   PubMed Web of Science ®Google Scholar
• StantonSE, DisisML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59. doi:10.1186/s40425-016-0165-627777769
   PubMed Web of Science ®Google Scholar
• AzimiF, ScolyerRA, RumchevaP, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J clin oncol. 2012;30(21):2678–2683. doi:10.1200/JCO.2011.37.853922711850
   PubMed Web of Science ®Google Scholar
• BoschatAC, MinetN, MartinE, BaroukiR, LatourS, SanquerS. CTP synthetase activity assay by liquid chromatography tandem mass spectrometry in the multiple reaction monitoring mode. JMS. 2019;54(11):885–893. doi:10.1002/jms.444231524312
   PubMed Web of Science ®Google Scholar
• YangC, LiuX, ChengT, et al. LYAR suppresses beta interferon induction by targeting phosphorylated interferon regulatory factor 3. J Virol. 2019;93(21). doi:10.1128/JVI.00769-19.
   Web of Science ®Google Scholar
• PrabhuL, HartleyAV, MartinM, WarsameF, SunE, LuT. Role of post-translational modification of the Y box binding protein 1 in human cancers. Genes Dis. 2015;2(3):240–246. doi:10.1016/j.gendis.2015.05.00130258867
   PubMedGoogle Scholar
• FinakG, BertosN, PepinF, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518–527. doi:10.1038/nm176418438415
   PubMed Web of Science ®Google Scholar
• RadvanyiL, Singh-SandhuD, GallichanS, et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA. 2005;102(31):11005–11010. doi:10.1073/pnas.050090410216043716
   PubMed Web of Science ®Google Scholar
• CurtisC, ShahSP, ChinSF, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352. doi:10.1038/nature1098322522925
   PubMed Web of Science ®Google Scholar
• CampbellTM, CastroMAA, de OliveiraKG, PonderBAJ, MeyerKB. ERalpha binding by transcription factors NFIB and YBX1 enables FGFR2 signaling to modulate estrogen responsiveness in breast cancer. Cancer Res. 2018;78(2):410–421. doi:10.1158/0008-5472.CAN-17-115329180470
   PubMed Web of Science ®Google Scholar
• FujiiT, KawaharaA, BasakiY, et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 2008;68(5):1504–1512. doi:10.1158/0008-5472.CAN-07-236218316615
   PubMed Web of Science ®Google Scholar
• BansalT, TanveerN, SinghUR, SharmaS, KaurN. Y-Box binding protein 1 expression in breast cancer and its correlation with hormone receptors and other prognostic markers. J Lab Physicians. 2018;10(4):420–425. doi:10.4103/JLP.JLP_58_1830498315
   PubMed Web of Science ®Google Scholar
• ItoT, KamijoS, IzumiH, KohnoK, AmanoJ, ItoK. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2012;133(1):145–159. doi:10.1007/s10549-011-1731-821863258
   PubMed Web of Science ®Google Scholar
• HabibiG, LeungS, LawJH, et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008;10(5):R86. doi:10.1186/bcr215618925950
   PubMed Web of Science ®Google Scholar
• DongS, NieH, LiD, et al. Molecular cloning and characterization of Y-box gene (Rpybx) from Manila clam and its expression analysis in different strains under low-temperature stress. Anim Genet. 2020;51(3):430–438. doi:10.1111/age.1291932091145
   PubMed Web of Science ®Google Scholar
• LyabinDN, EliseevaIA, OvchinnikovLP. YB-1 protein: functions and regulation. Wiley Interdiscip Rev RNA. 2014;5(1):95–110. doi:10.1002/wrna.120024217978
   PubMed Web of Science ®Google Scholar
• MittalS, BrownNJ, HolenI. The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn. 2018;18(3):227–243.29424261
   PubMed Web of Science ®Google Scholar
• McKinneyEF, SmithKG. T cell exhaustion and immune-mediated disease-the potential for therapeutic exhaustion. Curr Opin Immunol. 2016;43:74–80. doi:10.1016/j.coi.2016.09.00527744240
   PubMed Web of Science ®Google Scholar
• SicaA, SchioppaT, MantovaniA, AllavenaP. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42(6):717–727. doi:10.1016/j.ejca.2006.01.00316520032
   PubMed Web of Science ®Google Scholar
• HessmanCL, HildebrandtJ, ShahA, et al. YB-1 interferes with TNFalpha-TNFR binding and modulates progranulin-mediated inhibition of TNFalpha signaling. Int J Mol Sci. 2020;21(19):7076. doi:10.3390/ijms21197076
   PubMed Web of Science ®Google Scholar
• CaoX, ZhuN, LiL, et al. Y-box binding protein 1 regulates ox-LDL mediated inflammatory responses and lipid uptake in macrophages. Free Radic Biol Med. 2019;141:10–20. doi:10.1016/j.freeradbiomed.2019.05.03231153975
   PubMed Web of Science ®Google Scholar